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Abstract
Adjuvant hormonal therapy is administered to all early stage ER+ breast cancers, and has led to significantly improved
survival. Unfortunately, a subset of ER+ breast cancers suffer early relapse despite hormonal therapy. To identify molecular
markers associated with early relapse in ER+ breast cancer, an outlier analysis method was applied to a published gene
expression dataset of 268 ER+ early-stage breast cancers treated with tamoxifen alone. Increased expression of sets of genes
that clustered in chromosomal locations consistent with the presence of amplicons at 8q24.3, 8p11.2, 17q12 (HER2 locus)
and 17q21.33-q25.1 were each found to be independent markers for early disease recurrence. Distant metastasis free
survival (DMFS) after 10 years for cases with any amplicon (DMFS =56.1%, 95% CI =48.3–63.9%) was significantly lower
(P =0.0016) than cases without any of the amplicons (DMFS =87%, 95% CI =76.3% –97.7%). The association between
presence of chromosomal amplifications in these regions and poor outcome in ER+ breast cancers was independent of
histologic grade and was confirmed in independent clinical datasets. A separate validation using a FISH-based assay to
detect the amplicons at 8q24.3, 8p11.2, and 17q21.33-q25.1 in a set of 36 early stage ER+/HER2- breast cancers treated with
tamoxifen suggests that the presence of these amplicons are indeed predictive of early recurrence. We conclude that these
amplicons may serve as prognostic markers of early relapse in ER+ breast cancer, and may identify novel therapeutic targets
for poor prognosis ER+ breast cancers.
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Introduction
Hormone therapy is widely used for treatment of estrogen
receptor positive (ER+) breast cancer and has been shown to result
in significantly improved survival and lower rates of recurrence
(reviewed in [1,2]). However, a significant subset of ER+ breast
cancer patients treated with adjuvant hormone therapy suffer early
disease recurrence. These poor prognosis ER+ tumors tend to
have higher grade and show higher proliferative indices and may
not be ‘‘addicted’’ to ER –dependent signalling, making them
resistant to hormone therapy and prone to early relapse (reviewed
in [3–6]). A better understanding of the mechanisms underlying
the early relapse of some ER+ breast cancers may lead to better
prognostic assays, and to new targeted therapeutic strategies for
these poor prognosis cancers.
Several assays have been developed to distinguish ER+ patients
likely to do well with hormonal therapy from those likely to have
early disease progression. The best validated of these is the
Oncotype DxH assay [7] from Genomic Health, Inc., based on
RT-PCR measurement of mRNA levels of 21 genes. ER+ breast
cancer patients whose tumors have low ODx Recurrence Scores
(RS) do well with adjuvant hormonal therapy alone, while tumors
with high ODx RS are more likely to benefit from the addition of
chemotherapy to hormonal therapy. Other panels of genes, such
as the Genomic Grade Index panel [8], and clinical markers such
as histological grade, are also used to classify patients into good or
poor prognosis classes. In addition, molecular signatures from
clustering methods applied to gene-expression data are also able to
separate ER+ breast cancers into good prognosis (Luminal A) and
poor prognosis (Luminal B) classes [9–11]. However, several
studies have shown that, when the prognostic assays are compared
to the gene expression based sub-classification of breast cancers,
these assays are essentially identifying Luminal A tumors (low
grade, highly ER+ breast cancers, HER2-) as being good
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mostly intermediate-to-high grade, some with HER2 amplifica-
tion) as poor prognosis [12–14].
Although gene expression based assays such as Oncotype Dx
have prognostic and predictive utility, they do not identify the
biologic pathways driving resistance in the poor prognosis tumors.
Moreover the optimal strategy for ‘‘Intermediate Risk’’ ODx RS,
found in up to 30% of ER+ cancers, is not clear at present. In
contrast, the presence of the HER2 amplicon, in ER+ breast
cancers, has both clear prognostic value and identifies a clear and
effective therapeutic target. ER+ breast cancers with HER2-
amplification tend to have early recurrence if treated with
hormonal therapy alone, likely because the activation of the
HER2 pathway leads to independence from ER- mediated
signalling (see reviews above, also [15,16]). Moreover, therapy
that specifically targets HER2 has been shown to dramatically
improve outcome in HER2+ patients. Thus all breast cancers are
now routinely tested for the presence of HER2 amplification.
As HER2 amplicon genes are part of the 21 gene panel used in
determining the Oncotype Dx recurrence score (RS), breast
cancers with HER2 amplification generally have high RS, high
histological grade, and a high genomic grade and are easily and
correctly identified as poor prognosis by the assay. However, the
majority of poor prognosis ER+ cancers with high ODx RS do not
have HER2 amplification [14]. Indeed only patients with ER+
tumors and no evidence of HER2 amplification have Oncotype
DX assays performed in most clinical settings. At present there is
little insight into the mechanism driving estrogen independence
and growth in poor prognosis ER+/HER2- breast cancers.
In order to gain insight into the biology of these poor prognosis
ER+/HER2- breast cancers, we analyzed a public gene expression
data set of early stage ER+ breast cancers treated with tamoxifen
using a novel method. Sets of outlier genes whose expression
correlated with clinical outcome were analyzed to identify either
molecular pathways or enrichment of chromosomal regions. Four
separate regions of the genome were identified whose amplifica-
tion was highly predictive of poor prognosis in early stage ER+
breast cancers treated with tamoxifen. As expected, one of these
was the HER2 amplicon on 17q12 [17,18]; validating our
methods as being able to identify relevant amplicons. The other
three amplification regions were in 8q24.3, 8p11.2 and 17q21.33-
q25.1. Although these loci have previously been identified as
regions of amplification in subsets of breast cancer [19], their
association with tamoxifen resistance in ER+/HER2- breast
cancers is novel. The presence of these amplicons in ER+/
HER2- breast cancer and their association with poor prognosis
was validated in several independent data sets [20]. Taken
together, these findings demonstrate that these amplicons are
strong predictors of early relapse in ER+ breast cancers.
Results
Outlier Genes and Patterns Associated with Tamoxifen
Treatment Response
A gene expression dataset (published by Loi et al. [12,21])
containing 268 patients with early stage ER+ breast cancers
treated with local therapy and adjuvant tamoxifen with 9+ years of
available clinical follow-up data, was analyzed. Clinical charac-
teristics of this set have been previously described (Table S1).
Genes whose expression values were outliers in at least 10
samples in this dataset were identified and analyzed for their
correlation with distant metastasis free survival. Outlier genes for
which there was a significant difference in distant metastasis free
survival between samples having outlier expression when com-
pared to samples with normal expression, were identified and
retained (see Methods for details). Table S2 has the set of outlier
genes, hazard ratios, log-rank P values and outlier scores.
Principle component analysis (PCA) demonstrated that the
outlier genes separated into 3 clusters (Figure 1A). Survival analysis
of these clusters showed that one cluster contained genes whose
over-expression associated with poor prognosis, and the other two
contained genes over-expressed in good prognosis samples. The set
of outlier genes in each cluster was analysed using Gene Ontology
(GO) [22] to identify pathways and potential chromosomal
amplifications associated with outcome (Table S3). Pathways
enriched in over-expressed outliers associated with good prognosis
included development, cell adhesion, and immune response genes.
Of note, no clusters of outliers associated with good prognosis
suggestive of an underlying amplicon were detected. Outlier genes
whose over-expression was associated with poor prognosis had a
significant enrichment of genes in cell cycle pathways. Analysis of
outliers for clustering by chromosomal location identified putative
amplification of four chromosomal regions associated with poor
prognosis: 17q12, 17q21.33-q25.1, 8p11.2 and 8q24.3. The
presence of genomic amplification in any of these regions leads
to outlier expression of their genes, and is a marker of poor
prognosis in ER+ breast cancer.
Cell cycle pathway outliers contained genes associated with
proliferation and included many of the genes used to define the
Genomic Grade Index [8]. This confirms prior observations that
proliferation-associated genes are strong markers of poor prognosis
in ER+ breast cancer. The known amplicon on 17q12 [23]
associated with poor prognosis was also identified. This amplicon
contains the HER2 gene and is known to be associated with
relative resistance to hormonal therapy and poor prognosis in ER+
breast cancer. The other putative amplicons in 17q21.33-q25.1
[24–26], 8p11.2 [27,28] and 8q24.3 [19] have been previously
reported as amplified in subsets of breast cancers but their
association with tamoxifen resistance in ER+ breast cancer is a
novel finding. The full list of outlier genes identified in these
amplified chromosomal regions is listed in Table 1, with potential
oncogenes highlighted in red. Some of these genes have been
previously identified as playing a role in tumorigenesis or cancer
progression including, WHSC1L1 [29,30], CLTC [31–33], HSF1
[34], and LSM1 [35]. Of note the FGFR1 which has been
implicated in hormonal resistance in ER+ breast cancer [36], is
present at the edges of the 8p11.2 amplicon, but is not present in
our minimal amplicon defined by our analysis (see Table S2).
Similarly MYC, another oncogene reported to induce hormone
resistance in breast cancer, is upstream of the 8p24.3 amplicon
defined by our analysis, and is not associated with poor outcome in
this dataset (see Table S2).
For under-expressed outliers, a similar analysis showed that
relative under-expression of the cell cycle pathway was associated
with good prognosis, while under-expression of the immune
response and cell adhesion pathway was associated with poor
prognosis (Figure 1B). This mirrors the results for over-expressed
outlier genes and confirms the strong association of the cell cycle,
immune response and cell adhesion pathways with prognosis in
ER+ breast cancers.
Correlations between Cell Cycle Pathway and Putative
Amplicons in 17q12, 17q21.33-q25, 8p11.2, and 8q24.3
To examine the inter-relationship between the cell cycle
pathway and the four potential amplicons identified by our
analysis, a correlation matrix of all genes associated with poor
outcome was computed (Figure S1). Correlations between the
presence of each amplicon and any amplicon or the cell cycle
Amplicons in ER+ Breast Cancer
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pathway correlates partly with all the amplicons (Figure S1, Table
S4), suggesting that activation of cell cycle pathway is associated
with chromosomal amplifications in 17q12, 17q21.33-q25, 8p11.2,
and 8q24.3. Of note, the cell cycle genes themselves are not
located in these amplicon regions.
The association between cell cycle and putative amplicons was
further examined. Samples with enrichment of any of the four
amplicons or the cell cycle pathway were identified by requiring at
least 50% of gene markers in each group to be over-expressed, i.e.
marked as a high outlier in the respective sample. It was found that
in most samples (90.5%), over-expression of cell cycle genes display
at least one of the four chromosomal amplifications, suggesting a
causal relationship between tumor proliferation and the presence
of these amplicons.
However, chromosomal amplifications in 17q12, 17q21.33-q25,
8p11.2, and 8q24.3 have poor to medium correlations with each
other (Table S4), suggesting that the presence and effects of each
amplicon may be functionally independent.
Presence of Amplicons is Associated with Poor Outcome
in ER+ Breast Cancers in Multiple Independent Datasets
The effects of the presence of outliers in the cell cycle pathway,
and of each of the four amplicons on distant metastasis free
survival (DMFS) was determined. Presence of cell cycle pathway
genes was found associated with significantly lower DMFS (log-
rank P =0.0013), as well as higher hazard ratio (HR =9.71, 95%
CI =3.3–28.6) in ER+ breast cancers, compared to tumors that
lack this signature (Figure 2A). Presence of any of the four
amplicons was also associated with lower DMFS compared to
tumors without amplicons (Figure 2B). Hazard ratios for samples
with amplicons on 17q12, 17q21.33-q25, 8p11.2 or 8q24.3 vs. no
amplicons were 4.09, 3.14, 3.75, and 4.29 respectively, while log-
rank P values for the DMFS differences were 6.3e207, 3.0e204,
5.7e206, and 2.2e206.
For validation, we first analyzed a data set of 624 early stage
ER+ breast cancers for which relapse free survival data was
available. This dataset included patients from over 20 published
studies for whom gene expression data were combined as
previously described [37]. Samples from the training set (GEO
accession number GSE6532) were specifically excluded from this
combined data. The clinical characteristics of the rest of the
samples are listed in Table S5. This gene expression data was
analyzed to identify breast cancers that had outlier patterns
consistent with presence of the amplicons in 17q12, 17q21.33-q25,
8p11.2, and 8q24.3, as described in the Methods section. Kaplan-
Meyer curves of the survival fraction for ER+ cases showed that
samples which scored as having any of the putative amplicons, as
assayed by outlier analysis, had significantly poorer relapse free
survival compared to samples having no amplicons (Figure 2C),
validating our results.
In these datasets, the amplicons were imputed by analysis of
gene expression outliers in regions of known amplification. To
test whether the presence of genomic amplification is directly
responsible for these findings, a separate CGH array dataset
[38] (GEO accession number GSE22133) with 359 samples and
8.1 years of median follow-up survival information was
analyzed. We retained only the 222 ER+ samples for our
analysis (Table S6). Although we expect that the ER+ cancers
would have received adjuvant tamoxifen therapy, patients were
not uniformly treated and specifics of the exact treatments were
unavailable for this dataset. Copy number estimates obtained
from GEO were segmented using circular binary segmentation
(CBS) [39], followed by identification of significant amplification
peaks with the GISTIC [40] algorithm as described in [38].
Amplification peaks were detected in 17q12, 17q22, 8p11.2 and
8q24.3 which overlapped the regions previously found by gene
expression analysis. Correlation analysis between samples with
these amplicons showed little to medium associations (Table S7)
similar to the previously obtained values in Table S4.
Figure 1. PCA plots of high and low outliers. Principal component analysis of high outlier genes (A) and low outlier genes (B) associated with
differential distant metastasis free survival are shown. The figure represents the projection of each gene’s outlier profile on the first two principal
components of the corresponding matrix. Gene clusters associated with good prognosis are circled in blue while gene clusters associated with bad
prognosis are circled in red. Over-expressed genes associated with poor prognosis, which map to the chromosomal regions 8q24.3, 8p11.2, 17q21.33-
q25.1 and 17q12, and are associated with specific GO pathways are labeled with different colors.
doi:10.1371/journal.pone.0038575.g001
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ER+ breast cancers treated with tamoxifen.
Gene Hazard ratio P value Cytoband Start End
STARD3 2.23 4.19E203 chr17q12 35,046,940 35,073,248
ERBB2 1.91 2.16E202 chr17q12 35,110,005 35,122,109
GRB7 1.83 5.12E202 chr17q12 35,152,029 35,156,782
GSDML 2.51 1.72E203 chr17q12 35,326,079 35,328,194
PSMD3 1.78 3.57E202 chr17q12 35,390,607 35,407,732
PHB 2.48 7.96E204 chr17q21.33 44,836,413 44,847,246
SLC35B1 1.81 3.87E202 chr17q21.33 45,133,688 45,140,281
SUPT4H1 2.20 5.11E203 chr17q22 53,778,283 53,784,556
RAD51C 1.83 3.53E202 chr17q22 54,124,987 54,127,694
CLTC 2.04 8.80E203 chr17q23.1 55,052,102 55,126,906
PTRH2 1.96 1.27E202 chr17q23.1 55,129,449 55,139,638
ABC1 2.15 1.36E202 chr17q23.1 55,475,337 55,499,876
APPBP2 1.84 3.40E202 chr17q23.2 55,875,300 55,958,365
TRIM37 1.84 3.39E202 chr17q23.2 57,059,999 57,184,266
USP32 2.17 7.02E203 chr17q23.2 58,254,691 58,469,586
CYB561 2.22 5.45E203 chr17q23.3 58,864,245 58,869,052
CCDC44 1.89 3.97E202 chr17q23.3 59,038,377 59,039,456
PSMC5 2.19 5.37E203 chr17q23.3 59,258,832 59,263,111
PSMD12 1.98 1.94E202 chr17q24.2 62,764,494 62,793,171
KPNA2 1.76 4.87E202 chr17q24.2 66,031,848 66,042,970
ICT1 2.33 3.23E203 chr17q25.1 70,520,374 70,528,950
ATP5H 1.91 3.55E202 chr17q25.1 70,546,552 70,548,888
MRPS7 1.82 3.31E202 chr17q25.1 70,769,394 70,773,734
SAP30BP 1.81 4.18E202 chr17q25.1 71,175,038 71,214,431
SPFH2 1.85 2.55E202 chr8p11.2 37,713,267 37,734,476
PROSC 2.19 6.19E203 chr8p11.2 37,739,282 37,756,441
ASH2L 2.12 7.31E203 chr8p11.2 38,082,214 38,116,216
LSM1 2.39 1.08E203 chr8p11.2 38,140,017 38,153,183
WHSC1L1 2.28 3.90E203 chr8p11.2 38,293,091 38,358,947
BRF2 3.04 2.62E205 chr8p12 37,821,053 37,826,512
DDHD2 2.15 6.66E203 chr8p12 38,208,356 38,239,442
UBE2V2 2.11 9.08E203 chr8q11.21 49,083,545 49,136,681
ATP6V1H 2.45 1.47E203 chr8q11.23 54,828,192 54,832,484
MRPL15 2.27 3.53E203 chr8q11.23 55,210,341 55,223,011
COPS5 1.82 2.45E202 chr8q13.2 68,117,869 68,136,905
TCEB1 2.74 3.53E204 chr8q21.11 75,020,403 75,047,049
FAM82B 2.01 1.46E202 chr8q21.3 87,555,453 87,590,037
UQCRB 2.13 8.20E203 chr8q22 97,312,308 97,316,963
POLR2K 1.74 5.18E202 chr8q22.2 101,232,001 101,235,407
ATP6V1C1 1.81 4.87E202 chr8q22.3 104,102,463 104,152,473
EBAG9 1.80 4.48E202 chr8q23 110,621,485 110,646,565
YWHAZ 2.85 1.30E203 chr8q23.1 102,001,097 102,033,426
ENY2 2.70 3.08E204 chr8q23.1 110,415,745 110,425,074
RAD21 1.95 2.60E202 chr8q24 117,927,353 117,956,221
SQLE 2.13 1.49E202 chr8q24.1 126,100,439 126,102,952
MRPL13 2.93 1.90E204 chr8q24.12 121,477,267 121,526,557
SCRIB 2.39 5.07E203 chr8q24.3 144,945,082 144,968,239
SIAHBP1 1.97 1.59E202 chr8q24.3 144,970,536 144,983,471
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of 17q12, 17q22, 8p11.2 and 8q24.3 regions were determined
using GISTIC and Kaplan-Meier estimator, and are shown in
Figure 2D. This analysis showed that the presence of an amplicon
in any of these four regions is associated with significantly worse
outcome. Hazard ratios for samples with amplicons in 17q12,
17q22, 8p11.2 and 8q24.3 vs. no amplicons were 2.61, 3.02, 2.65,
and 2.12 respectively, while log-rank P values for the survival
difference were 6.8e204, 7.3e205, 1.3e203, and 6.7e203. Of
note, 17q22 as identified by GISTIC, is a peak region included in
the previously defined amplicon 17q21.33-q25 which contains a
considerable number of outlier genes in the 17q22 locus (see
Table 1).
Associations between Presence of Amplicons and
Oncotype Dx Recurrence Score
A validated marker of poor outcome in ER+ breast cancers with
hormonal treatment is the Oncotype Dx assay [7]. This assay uses
a weighted, linear combination of the expression of 21 genes to
generate a single recurrence score RS. The genes used in this assay
consist of HER2, GRB7, GSTM1, CD68, BAG1, invasion
markers (MMP11, CTSL2), proliferation markers (Ki67,
STK15, Survivin, CCNB1, MYBL2) as well as estrogen and
reference markers. We used this gene panel and to generate a
relative Oncotype Dx Recurrence Score using normalized
expression levels and published weights [7]. This calculation of a
relative Oncotype Dx recurrence score from gene expression array
data is based on prior studies which have such relative scores to
correlate with both outcome and molecular subtype [9,41]. This
relative RS score was able to separate poor prognosis samples from
good prognosis samples in the tamoxifen treated sample set of 268
patients, validating this relative ODx score as being prognos-
tic(Figure S2). We found (Figure S3) that the presence of any of
these amplicons was associated with higher recurrence scores,
while ER+ cancers lacking the amplicons had lower recurrence
scores. A potentially significant finding was that the relative
Oncotype Dx scores of tumors with amplicons 17q21.33-q25.1,
8p11.2 and 8q24.3 was lower than that of tumors with HER2
amplification (Figure S3), while their prognosis was similarly poor
(Figure 2B). This observation suggests that Oncotype Dx may, in
some cases, underestimate the risk of poor prognosis in tumors
with these amplifications, and that some of tumors classified as
‘‘intermediate risk’’ by Oncotype Dx may in fact be high risk
tumors.
To further test the hypothesis that regions 17q21.33-q25.1,
8p11.2 and 8q24.3 are likely to be amplified in ER+/HER2-
breast cancer samples having high Oncotype Dx recurrence scores
because of upregulation of cell-cycle genes, a set of 14 ER+/
HER2- breast cancer samples with known Oncotype Dx scores
was evaluated for the presence of 17q21.33-q25.1, 8p11.2 or
8q24.3 amplifications using FISH. Out of 14 samples, 8 had high
recurrence scores (RS) (.30) and 6 had low scores (,18). As
shown in Figure S4 and Table 2, cancers with high RS had
amplification of at least one of these regions, while almost all
cancers with low RS did not exhibit any amplification at these
chromosomal locations.
Associations between Presence of Amplicons and
Histologic Grade
Histologic grade is also a strong predictor of outcome in ER+
breast cancer, with low grade tumors having good outcome with
hormone therapy and high grade tumors having poor outcome in
this setting [42]. In order to rule out the possibility that the
presence of the amplicons is a surrogate for high histologic grade, a
multivariate Cox analysis (Table 3) was performed on the training
data set (GEO accession number GSE6532) to explore the relation
between the presence of any of the four amplicons and other
clinical markers (patient age, tumor size, node status, tumor grade
and HER2 status) as well as the relative Oncotype Dx score
calculated from gene expression data. We found that the presence
of amplicons was a significant predictor of distant metastasis (HR
=2.53, P =0.0067), more so than, tumor size (HR =1.38, P
=0.0180), histologic grade (HR =0.44, P =0.0959) or ODx RS
(HR =1.08, P =0.3838). If the amplicon covariate was removed
from the Cox analysis, then significant predictors of distant
metastasis become ODx RS (HR =1.19, P =0.0487) and tumor
size (HR =1.29, P =0.0330).
Table 1. Cont.
Gene Hazard ratio P value Cytoband Start End
GRINA 2.07 1.12E202 chr8q24.3 145,136,247 145,139,570
EXOSC4 2.14 7.84E203 chr8q24.3 145,205,516 145,207,538
CYC1 2.45 4.97E203 chr8q24.3 145,221,982 145,224,415
SHARPIN 2.12 1.84E202 chr8q24.3 145,225,527 145,230,852
C8orf30A 1.80 4.97E202 chr8q24.3 145,264,659 145,267,608
BOP1 2.30 5.71E203 chr8q24.3 145,456,867 145,485,928
HSF1 2.36 1.24E202 chr8q24.3 145,497,218 145,498,193
FBXL6 2.62 6.13E204 chr8q24.3 145,549,899 145,552,940
GPR172A 2.99 2.81E204 chr8q24.3 145,553,131 145,555,738
VPS28 2.34 2.53E203 chr8q24.3 145,619,807 145,623,174
RPL8 2.18 6.48E203 chr8q24.3 145,985,957 145,988,332
ZNF7 2.17 8.43E203 chr8q24.3 146,023,747 146,043,697
ZNF250 1.83 3.51E202 chr8q24.3 146,076,967 146,079,026
C8orf33 1.94 1.63E202 chr8q24.3 146,248,629 146,251,814
List of genes associated with early relapse on chromosomes 8 and 17. Highlighted in bold are cancer related genes of interest.
doi:10.1371/journal.pone.0038575.t001
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discriminate outcome in intermediate grade tumors, which is a
clinical grade category with unclear prognostic significance. Two
datasets, (GSE6532 training set with gene expression data, and
GSE22133 validation set with CGH data) where annotated
pathologic grade information was available were analyzed.
Kaplan-Meier curves comparing distant relapse rates for interme-
diate grade tumors with any of these four amplicons versus cases
Figure 2. Patients with cell cycle pathway activation or outliers patterns consistent with amplification of 17q12, 17q21.33-q25.1,
8p11.2 and 8q24.3 show poor outcome under tamoxifen treatment. A) Kaplan-Meier curves of the samples in the primary dataset (GSE6532)
enriched for over-expressed cell cycle genes versus the rest of samples that don’t show this feature. Patients with cell cycle activated genes show a
significant decrease in distant metastasis free survival rate (HR =9.71, 95% CI =3.3–28.6; P,0.0001). B) Kaplan-Meier curves of the ER+ samples in the
primary dataset (GSE6532) stratified by presence of putative amplicons in 17q12, 17q21.33-q25.1, 8p11.2 and 8q24.3. Patients that show any one of
the chromosomal amplifications have significantly higher relapse rates when compared to samples without any amplifications: 17q12 (HR =4.09,
95% CI =3.84–21.99; P =6.3e207), 17q21.33– q25.1 (HR =3.14, 95% CI =2.17–13.62; P =3.0e204), 8p11.2 (HR =3.75, 95% CI =3.18–18.31; P
=5.7e206), and 8q24.3 (HR =4.29, 95% CI =4.32–34.08; P =2.2e206). C) Analysis of combined gene expression data of 624 ER+ breast cancers from
multiple published data sets. Outlier analysis was performed to identify cases with evidence of amplification at 17q12, 17q22, 8p11.2, and 8q24.3 and
those without evidence of any amplification. Kaplan-Meier curves of relapse free survival for ER+ samples with each of the four amplicons, and
samples containing no amplicon are plotted: 17q12 (HR =2.30, 95% CI =1.45–3.64; P =4.0e204), 17q22 (HR =3.07, 95% CI =1.99–4.73;
P,1.0e204), 8p11.2 (HR =1.96, 95% CI =1.23–3.13; P =4.9e23), 8q24.3 (HR =2.38, 95% CI =1.60–3.55; P,1.0e204) D) Kaplan-Meier curves of
overall survival for the ER+ samples in the test CGH dataset (GSE22133) with each of the 4 amplicons, as well as samples that don’t have any of the
chromosomal amplifications. Analysis of the CGH data identified amplification peaks at each of the four regions that overlap with the previously
identified loci. Patients that show any one of the chromosomal amplifications have significantly higher event rates than those without any of the
amplifications: 17q12 (HR =2.61, 95% CI =1.51–5.51; P =6.8e204), 17q22 (HR =3.02, 95% CI =1.76–5.18; P =7.3e205), 8p11.2 (HR =2.65, 95% CI
=1.48–4.74; P =1.3e203), and 8q24.3 (HR =2.12, 95% CI =1.24–3.65; P =6.7e203). Log-rank tests were used to calculate all the P values.
doi:10.1371/journal.pone.0038575.g002
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GSE6532, were significantly different (HR =3.22, 95% CI =1.6–
6.5; P =0.0012). This was true also for Kaplan-Meier curves
comparing overall survival for intermediate grade cancers with
any of the 4 amplicons versus cases with none of the amplicons
(Figure 3B) in the test set GSE22133 (HR =3.01, 95% CI =1.2–
7.6; P =0.0200). Together, these results demonstrate that the
amplicon associated risk categories have a discriminatory power
beyond that of standard histologic grade.
FISH-based Assay has Potential Prognostic Value in ER+/
HER2- Breast Cancers Treated with Hormone Therapy
A multiplexed FISH assay to detect 8p11.2, 17q22 and
8q24.3 amplicons in FFPE sections was developed using
prelabeled FISH probes from validated BACs (Bacterial
Artificial Chromosomes). The specificity of each probe was
tested on metaphase chromosome spreads and hybridized to the
corresponding chromosomal locations. The FISH assay was
applied to 36 ER+/HER22 samples from the MicMa cohort
that were treated with adjuvant hormonal therapy [20]
(Figure 4). Tumor samples, present in tissue microarray format,
were scored for amplification of each amplicon by averaging
signals in 20 tumor cells/sample. The KM curves for systemic
relapse free survival in this cohort for patients with and without
any amplicon are shown in Figure 4. There is a trend for
decreased relapse-free survival in patients scored as having any
amplicon, vs. having no amplicon, but given the small sample
size, this did not achieve statistical significance (P=0.1041). The
thresholds for amplification were optimized using the outcomes
in this sample set, and thus require independent validation in
future studies. Of note, very few relapses occurred earlier than
1500 days in the no-amplicon group, whereas the majority of
relapse in the any-amplicon group occurred before 1500 days.
Discussion
Currently Oncotype Dx assays are routinely used to predict
outcome and guide treatment for early stage ER+/HER2-
breast cancer patients in the US. A high Oncotype Dx
recurrence score can identify patients likely to have poor
outcome with hormonal therapy alone, and who may benefit
most from the addition of chemotherapy. However, such
prognostic assays are expensive, often have intermediate risk
scores with unclear predictive value, do not give biological
insight into mechanisms driving poor prognosis, and do not
identify potential therapeutic targets.
The results presented in this paper demonstrate that the
presence of amplifications in chromosomal regions 17q21.33-
q25.1, 8p11.2 and 8q24.3 are strong markers of poor prognosis
in ER+/HER2- breast cancers. Our results suggest that these
amplicons may function in a manner similar to HER2
amplification in identifying ER+ breast cancers with poor
outcome and relative resistance to hormone therapy. In our
primary dataset of 268 patients treated with tamoxifen, of the
44 patients who suffered distant metastasis within the first 4
years after diagnosis, only 30% were identified as having only
17q12 (HER2+) amplification, while an additional 42% had
amplification of one of the three other amplicons. These results
suggest that the presence of other amplicons, besides HER2, is
associated with early relapse in ER+ breast cancer.
The presence of these amplicons is also associated with higher
expression of proliferative genes/cell cycle genes that drive a high
Oncotype Dx (ODx) recurrence score. Direct analysis of clinical
specimens for amplification of these regions using FISH also
Table 2. FISH scores for ER+/HER2- breast cancer tissue
samples.
17q22 8q24.3 8p11.2 Oncotype Dx
amplified amplified amplified 46
not amplified not amplified amplified 42
borderline not amplified amplified 38
amplified borderline borderline 36
borderline amplified borderline 33
amplified amplified amplified 44
amplified amplified borderline 42
borderline borderline borderline 34
no signal not amplified not amplified 13
no signal not amplified not amplified 8
not amplified not amplified not amplified 5
borderline not amplified not amplified 12
not amplified no signal no signal 11
not amplified not amplified not amplified 11
Fluorescence in situ hybridization (FISH) results for 14 paraffin embedded ER+/
HER2- breast cancer samples. Scores were calculated as the average number of
spots over 20 cancer cells for each chromosomal location and separated into
amplified, not amplified and borderline classes as follows: (.4 amplified; 2–4
borderline; ,2 not amplified). The last column lists the associated Oncotype Dx
score for each sample, 8 have high scores (.31) while 6 have low scores (,18).
doi:10.1371/journal.pone.0038575.t002
Table 3. Multivariate Cox analysis of Age, Tumor size, Tumor
grade, Lymph node status, Progesteron status, Oncotype Dx
recurrence score, Her2 amplicon (17q12) and Any amplicon
(17q12, 17q21.33-q25.1, 8p11.2 or 8q24.3).
Covariate P values Hazard ratio (95% CI)
Analysis without the combined amplicons
Age 0.8935 1.00 (0.97–1.03)
Tumor size 0.0330 1.29 (1.02–1.62)
Low grade 0.0688 0.41 (0.16–1.07)
High grade 0.2577 0.67 (0.33–1.34)
Lymph node negative 0.3866 0.77 (0.43–1.39)
Onctoype Dx recurrence score 0.0487 1.19 (1.00–1.41)
Her2 amplicon 0.9245 1.05 (0.39–2.82)
Analysis with the combined amplicons
Age 0.9853 1.00 (0.97–1.03)
Tumor size 0.0180 1.38 (1.05–1.70)
Low grade 0.0959 0.44 (0.17–1.15)
High grade 0.2372 0.66 (0.34–1.31)
Lymph node negative 0.4073 0.78 (0.43–1.40)
Onctoype Dx recurrence score 0.3838 1.08 (0.91–1.29)
Her2 amplicon 0.8021 0.89 (0.35–2.23)
Any amplicon 0.0067 2.53 (1.30–4.93)
219 samples from the primary data set (GSE6532) had clinical information for all
analyzed covariates. Cox proportional-hazard regression was performed on the
reduced data set (with and without ‘Any amplicon’ covariate) resulting in a
significant overall model fit (P =0.0005 and P =0.0001).
doi:10.1371/journal.pone.0038575.t003
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associated with high ODx scores, while tumors that lack any of the
amplicons have low recurrence ODx scores. This indicates that
identification of chromosomal amplifications in defined regions, by
a cost effective FISH assay, may be a clinically useful biomarker
for predicting poor outcome in early stage ER+/HER2- breast
cancers. Moreover, analysis of relative ODx scores in gene
expression data sets suggests that ODx may underestimate risk
associated with presence of amplicons, and that some tumors
classified as intermediate risk by ODx assay may instead be poor
prognosis tumors marked by a high risk amplicon. These finding
will need to be validated in future studies analyzing a larger set of
ER+ breast cancers with known ODx scores and clinical outcome.
Figure 3. Analysis of intermediate grade tumors by presence of amplicons. Kaplan-Meier curves comparing distant relapse rates for
intermediate grade cancers with any of the 4 amplicons versus cancers with none of the amplicons (A) in the training set GSE6532 (HR =3.22, 95%
CI =1.6–6.5; P =0.0012). Also shown Kaplan-Meier curves comparing overall survival for intermediate grade cancers with any of the 4 amplicons
versus cancers with none of the amplicons (B) in the test set GSE22133 (HR =3.01, 95% CI =1.2–7.6; P =0.0200).
doi:10.1371/journal.pone.0038575.g003
Figure 4. Analysis of amplicon status using multiplexed FISH in a cohort of tamoxifen treated ER+/HER2- breast cancers. ER+/HER2-
samples with systemic relapse events were probed for the amplification of 8p11.2, 17q22 and 8q24.3 by multiplexed FISH assay as described in
Methods. A) Out of 36 samples, 15 had at least one region amplified. Kaplan-Meier curves for relapse free survival is shown for cancers having at least
one amplicon vs cancer having no amplicons (HR =2.31, 95% CI =0.66–8.06; P =0.1041 (Gehan-Willcoxon) or P =0.1886 (Mantel-Cox)). B) A typical
image of multicolor FISH in a breast cancer specimen. This cell has evidence of amplification of both 17q23.1 and 8p11 loci, but normal 8q24 loci.
doi:10.1371/journal.pone.0038575.g004
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cancers, the chromosomal regions 17q21.33-q25.1, 8p11.2 and
8q24.3 contain oncogenes that may be valuable as therapeutic
targets for novel drug therapies. Genes in the 8p11.2 region
identified as putative oncogenes and therapeutic targets include U6
snRNA-associated Sm-like protein (LSM1), Wolf-Hirschhorn syn-
drome candidate 1-like 1 (WHSC1L1), and the RNA Polymerase
III subunit BRF2 in region 8p11.2. Of note BRF2 has the highest
associated HR, and was recentlyidentified asa putative oncogenein
squamous cell lung cancer [29,30,34,43]. Fibroblast growth factor
receptor-1 (FGFR1), recently identified as a putative driver of
endocrine resistance in breast cancer [36], is at the edges of the
8p11.2 amplicon that we found associated withearly relapse in ER+
breast cancer treated with tamoxifen. Its outlier profile is associated
with poor survival with hazard ratio of 1.8 and a log-rank P value of
0.046 (Table S2). However, in our analysis FGFR1 is not the
strongest candidate in this region, and was not present in our
minimal amplicon region defined by our methods.
As seen in Figure S1, the majority of outlier genes associated with
poor prognosis on the q arm of chromosome 8 are clustered in the
region 8q24.3 with the rest of them scattered all the way to 8q11.2.
Thissuggeststhat insomecases the wholeq armof chromosome 8 is
amplified or that there are a number of amplicons on 8q that
correlate with 8q24.3. Slightly more upstream of 8q24.3 there is a
well known oncogene MYC, a key estrogen effector, that has been
reported to induce tamoxifen resistance when over-expressed [44].
Although MYC could also contribute to the effect of this amplicon
on early relapse, it was not identified in our analysis as strongly
associated with differential survival (log-rank P =0.042, Table S2)
compared to more distal genes, suggesting it may contribute to only
a minority of cases containing this amplicon. Other potential genes
driving tumorigenesis in 8q24.3 include Heat Shock Transcription
Factor1 (HSF1),whichhas been showntobe a powerfulpotentiator
of tumorigenesis [29,30,34]. Also of interest is YWHAZ, a member
of the 14-3-3 family of proteins. High expression of YWHAZ has
been associated with poor clinical outcome in ER+ breast cancer
[45].Down-regulationofYWHAXcanrestoretamoxifensensitivity
to tamoxifen resistant populations of MCF-7 cells, suggesting it may
play a direct role in mediating hormone resistance [46].
Of the chromosomal regions identified in this study, 17q21.33-
q25.1 is the least understood. Situated downstream of a much
better known amplicon 17q12 (HER2+), it is known to be
amplified and correlated with high grade tumors and poor
prognosis [26]. However, there is still no definite identification of
driver oncogenes in this region. Possible candidates are CLTC,
involved in gene fusions in B-cell lymphomas and non-small cell
lung carcinomas, and RAD51C involved in DNA repair and
homologous recombination. The gene with highest HR for relapse
in this region is Prohibitin (PHB), a transcriptional regulator that
has been shown to have both oncogenic and tumor suppressor
capability in different contexts. Of note PHB has been reported to
associate with and inhibit ER-mediated transcriptional function,
suggesting it may play a role in modulating ER-function [47].
Another gene associated with early relapse is Cyclin D1 (CCND1,
log-rank P =5.7e-06, Table S2) [48] located on chromosomal band
11q13,whichisanotherwellknownamplificationsite[49].However
CCND1 is also a cell cycle marker and its expression is associated
with proliferation. Thus the association of high CCND1 expression
withpooroutcomemayinpartreflectitsroleinproliferationand not
just as a driver oncogene. This region was not identified as an
independent potential amplicon in our analysis. Intriguingly there
are reports of an association between 11q13 amplification and
amplification of8p12[38,50,51] inbreastcancers, with somereports
demonstrating a physical association between these domains [50].
Analysis for the presence of 17q21.33-q25.1, 8p11.2 and 8q24.3
amplicons by a multiplexed FISH assay in 36 ER+/HER2-
samples from the MicMa cohort showed there is a trend towards
decreased relapse free survival in patients who have amplicons
compared to those who do not. Although small numbers limit
statistical significance, these results are encouraging and suggest
that a FISH-based assay could be developed as a prognostic tool.
Future studies that evaluate large, well annotated clinical data sets
are necessary to validate the FISH assay and determine whether
these amplicons can be of used as predictive and prognostic
markers in ER+ breast cancer.
In summary, the data presented here suggest that amplification
of chromosomal regions 17q21.33-q25.1, 8p11.2 and 8q24.3 is
strongly associated with early relapse in early stage ER+/HER2-
breast cancers treated with hormonal therapy, and correlates with
high Oncotype Dx recurrence scores. These chromosomal regions
also contain genes whose over-expression may directly drive early
relapse and/or hormone independence in ER+ breast cancers,
and may be candidates for targeted therapy. Assays to identify the
presence of amplicons may then both identify patients at high risk
of relapse with hormonal therapy alone, and also potentially help
determine what targeted therapy may be most appropriate to
improve outcome in these poor prognosis cancers.
Materials and Methods
Ethics Statement
Clinical samples obtained at CINJ-UMDNJ were pre-existing
archived samples that were de-identified and obtained without
individual consent under a protocol approved by the Institutional
Review Board of UMDNJ (Piscataway/NewBrunswick Campus).
Samples from Radium Hospital for which clinical outcome data
were available were obtained with written patient consent under a
protocol approved by Regional Ethical Committee of South
Eastern Norway (REK sør-øst).
Data Processing
Three breast cancer gene expression datasets from Loi et al.
[12,21] were downloaded from (GEO:www.ncbi.nlm.nih.gov/geo,
accession number GSE6532). The sets are abbreviated as KIT,
OXFT and GUYT representing the institutions of origin: Uppsala
University Hospital, John Radcliffe Hospital, and Guys Hospital.
They comprised of data from 81, 109 and 87 ER+ breast cancer
samples from patients treated with tamoxifen with 9 years median
clinical follow-up on Affymetrix U133A/B (KIT & OXFT) and
U133Plus2 (GUYT) platforms. After MAS5 normalization, probes
were retained only for genes found on both platforms. Expression
valueswerelog2 transformedandmultipleprobes/genecompressed
to the probe with highest median expression across samples.
Supervised Outlier Analysis of Gene Expression Datasets
Expression values were median centered and divided by the
median absolute deviation (MAD) as described in Tomlins et al.
[52]. This step was performed separately for KIT, OXFT and
GUYT datasets to avoid distribution biases. Outlier low/high cut-
off values for each gene were defined as those which were outside
the 10/90% quantile cutoffs across samples (results were
insensitive to varying the quantile cut-off by +/25%). High/low
outlier genes for each sample array were identified using these
cutoffs. The dataset is now reduced to three binary matrices of size
Ngenes xN samples, one matrix for non-outliers and one each for high
and low outliers. This process was implemented separately for
each dataset (KIT, OXFT, GUYT) and the resulting matrices
merged by concatenation over samples.
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in sample j was/was-not an outlier, wereanalysed further. Geneswith
,10 outliers across samples were discarded as not informative for
statistical inference. For each remaining gene, the distribution of
outliers across samples defines two classes: the sample set with
‘‘aberrant’’ (outlier) expression and the sample set with ‘‘normal’’
expression. Kaplan-Meier curves were used to identify the genes
where these classes had a significant differential survival based on a
log-rank test at p,0.05 (complete list in Table S2).
Identification of Predictive Gene Patterns for Tamoxifen
Sensitivity
Do the outlier genes defined as above represent gene categories
of clinical interest? For this to be true and statistically significant,
sets of genes must exist with similar outlier classes - i.e., they must
be over/under-expressed in roughly the same set of samples. This
corresponds to identifying tightly correlated clusters of outlier
genes and samples in the binary matrices B1 or B2. These were
identified using the Phi coefficient (equivalent to a Pearson
correlation between rows of matrices B1 or B2) as follows:
Let C1 and C2 be the covariance matrices between the rows of B1
and B2 respectively. Then, R1,2(i,j)~C1,2(i,j)
  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
C1,2(i,i)C1,2(j,j)
p
isthematrixofcorrelation coefficientsbetween the outlierprofilesof
the genes in B1 or B2. Clusters of tightly correlated genes were
identified by iteratively removing row i and column i with P
j D(i,j)ƒ1 where D(i,j)~1 if R1,2(i,j)w0:5 and D(i,j)~0
otherwise, until a stable set was obtained. Here, stability means
that the size of the reduced matrix R’ stops changing. PCA plots of
the resulting reduced matrices B1 and B2 were used to identify
distinct groups of highly correlated genes for further analysis (eg.
pathway enrichment [22]).
The identified genes were mapped to chromosomal locations
and amplified regions identified using a sliding window 25 genes
wide with a pace of 5 genes (varying the window size and/or pace
by 5–10 genes did not affect results. The Fisher Exact test [53] was
used to assess significance. The Benjamini-Hochberg method [54]
was used to implement FDR ,5% by converting p-values to q-
values. For each array, chromosomal regions with q ,0.05 were
marked as potential amplifications and ordered by frequency in
the cluster sample set.
Relative Oncotype Dx Scores
The Relative Oncotype Dx score is calculated using normalized
gene expression values of the set of genes from the original score
together with their published weights [7]. The genes used in
calculating this score are: HER2, GRB7, GSTM1, CD68, BAG1,
invasion markers MMP11, CTSL2, proliferation markers Ki67,
STK15, Survivin, CCNB1, MYBL2 and hormonal markers ER,
PGR, BCL2, and SCUBE2. A separate score is calculated for each
group and then combined in a final score:
s1~0:9|GRB7z0:1|ERBB2
s2~(0:8|ERz1:2|PGRzBCL2zSCUBE2)=4
s3~(SurvivinzKi67zMYBL2zCCNB1zSTK15)=5
s4~(CTSL2zMMP11)=2
ODX~0:47|s1{0:34|s2z1:04|s3z0:1|s4
z0:05|CD68{0:08|GSTM1{0:07|BAG1
Fluorescence in situ Hybridization (FISH)
Prelabeled FISH probes for BAC clones RP11-1065N2, RP11-
90P5 and RP11-1136N16 were purchased (Empire Genomics,
Buffalo, NY) and tested on metaphase chromosome spreads. FISH
experiments were performed on 14 4 mm paraffin embedded
breast cancer tissue slides, collected from ER+/HER2- breast
cancer patients treated in 2007–2009 at Robert Wood Johnson
University Hospital, New Jersey, USA. Hybridization was
performed on hybrite for 16–24 hours at 37uC, and slides washed,
first with 4x SSC for 3 min at 37uC then with 0.1% NP-40 (Vysis,
Downers Grove, IL, USA) for 30 sec at room temperature. Slides
were scored for chromosomal amplification by counting signals in
20 tumor cells and averaging.
A multiplex FISH assay was also developed to score the
amplicons on specimens from 36 ER+/HER2- patients treated
with hormone therapy from the MicMa cohort that were
available in a tissue microarray format [55]. The probes were
labelled by Nick translation with nucleotides labelled with
Green-dUTP, Alexa Fluor 594-5-dUTP and HyPer5 dCTP,
respectively. Scoring of FISH signals was done by acquiring z-
stacks of the whole thickness of each sample and using a Nikon
Ti microscope attached to a Yokogawa spinning-disk confocal
unit. Non-tumor cells such as fibroblasts or lymphocytes were
used as internal controls. The amplicon count for the sample
was the average number of counts over 20 cells. We consider
the sample to have an amplicon if its amplicon count is $3.5
for 8p11.2, $4.0 for 17q12 and $2.8 for 8q24.3. These
thresholds were obtained by finding the optimal thresholds
associated with survival difference between the cases that had at
least one amplicon against the cases that had none in this
sample set.
Supporting Information
Figure S1 Clustergram of the correlation matrix be-
tween selected over-expressed genes identify pathways
and amplicons for poor survival under tamoxifen
treatment. The Phi coefficients between gene pairs of highly
expressed outlier genes associated with tamoxifen resistance in
Figure 1A produce a correlation matrix. The figure shows the
resulting heatmap of this correlation matrix using hierarchical
clustering using Pearson correlation distance and complete
linkage. Genes in the same pathway or chromosomal region are
clustered together as marked.
(TIF)
Figure S2 Survival curves for samples with high/low
Oncotype Dx scores. Kaplan-Meier curves showing signifi-
cantly lower survival (HR =2.81, 95% CI =1.7–4.5; P,0.0001)
for tumor samples with high Oncotype Dx scores (ODx score .0)
versus low Oncotype Dx scores (ODx score ,0).
(TIF)
Figure S3 Oncotype Dx and presence of amplicons in
ER+ breast cancer. Relative Oncotype Dx scores calculated
across all 3 datasets (GSE6532) as outlined in Methods, are shown
as mean values with standard errors for each group of samples
listed on the vertical axes. Note that the Oncotype Dx scores for
patients with the three novel amplicons are less than that for
HER2 amplicon, in spite of their similar poor survival. This
suggests that Oncotype Dx does not adequately assess the presence
of these novel amplicons, and may underestimate risk in some
cases.
(TIF)
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cohort of tamoxifen treated ER+/HER22 breast can-
cers. This figure shows typical FISH images from analysis of
FFPE slides for samples with/without amplicons using probes
specific to each amplicon.
(TIF)
Table S1 Clinical information file. Excel 2003 file contain-
ing clinical characteristics of the breast tumor samples used in the
gene expression analysis from the study by Loi et al. [12,21].
Relative Oncotype Dx scores together with pathway/amplicon
presence for each sample are also listed.
(XLS)
Table S2 Survival associated with outlier genes. Excel
2003 file containing a table of outlier association results for all
genes used in the analysis. Along with the outlier scores and
hazard ratios, corresponding P values are also listed.
(XLS)
Table S3 Gene patterns associated with tamoxifen
response. Gene Ontology pathway/chromosomal location
enrichment results in the primary gene expression dataset
GSE6532. Significance was assessed using Fisher Exact Test.
(DOC)
Table S4 Sample correlations between gene patterns
associated with tamoxifen resistance. Sample correlations
between cell cycle pathway and amplicons associated with
tamoxifen resistance in the primary gene expression dataset
GSE6532. Values represent Phi coefficients measuring the
strength of association between the group of samples that over-
express cell cycle genes and amplicons 17q12, 17q21.33-q25.1,
8p11.2 and 8q24.3. The last column lists the percentage counts of
ER+ samples with the associated pathway/amplicons. Highlighted
in bold are correlation values significant at P,0.01 except for self
correlations.
(DOC)
Table S5 Clinical information file. Excel 2003 file contain-
ing clinical characteristics of the breast tumor samples used in the
analysis of the combined gene expression data set from the study
by Gyo ¨rffy et al. [37]. Amplicon presence as found by the
unsupervised outlier analysis are also listed.
(XLS)
Table S6 Clinical information file. Excel 2003 file contain-
ing clinical characteristics of the breast tumor samples used in the
CGH data analysis. Amplicon presence as found by GISTIC is
also listed for each sample.
(XLS)
Table S7 Sample correlations between amplicons
17q12, 17q22, 8p11.2 and 8q24.3 in an independent
CGH array data set. Phi coefficients measuring the strength of
association between amplicons 17q12, 17q22, 8p11.2 and 8q24.3
in the test CGH dataset GSE22133. The last column lists the
percentage counts of ER+ samples with the associated amplicons.
Highlighted in bold are correlation values significant at P,0.01
except for self correlations.
(DOC)
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